KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Other Non-Current Assets (2017 - 2025)

Astrazeneca (AZN) has 3 years of Other Non-Current Assets data on record, last reported at $559.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 57.02% year-over-year to $559.0 million; the TTM value through Dec 2025 reached $559.0 million, up 57.02%, while the annual FY2025 figure was $559.0 million, 57.02% up from the prior year.
  • Other Non-Current Assets reached $559.0 million in Q4 2025 per AZN's latest filing, up from $356.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $559.0 million in Q4 2025 and bottomed at $274.0 million in Q4 2023.
  • Average Other Non-Current Assets over 3 years is $396.3 million, with a median of $356.0 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: grew 29.93% in 2024, then skyrocketed 57.02% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $274.0 million in 2023, then grew by 29.93% to $356.0 million in 2024, then surged by 57.02% to $559.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $559.0 million in Q4 2025, $356.0 million in Q4 2024, and $274.0 million in Q4 2023.